OncoSec Collaborates with Smart Patients to Form New Online Community for Patients
Co-Founded by Former Chief Health Strategist of Google
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors, is one of the first to partner with Smart
Patients: a new online community where patients with life-threatening
conditions who are looking for or participating in clinical trials can
share their feedback and experiences. Google’s former Chief Health
Strategist, Roni Zeiger, will be speaking at the TEDMED
conference in Washington, D.C. today to unveil the new website.
OncoSec is working with Smart Patients to create a community for Merkel
cell carcinoma (MCC) patients. MCC is an extremely rare and aggressive
form of skin cancer that currently has no approved therapies. OncoSec is
conducting the only active Phase II immunotherapy trial that is focused
specifically on the disease. The Smart Patients partnership will provide
valuable insight from patients to help improve clinical trial design and
enable better collaboration with patients.
“We’re excited to be working with Dr. Zeiger, and to be a part of
creating this valuable resource for the Merkel cell community,” said
OncoSec’s CEO, Punit Dhillon. “One of the most frightening parts of
being diagnosed with a rare disease like MCC is a lack of information
about the condition and treatment options. Smart Patients is providing
an important resource to help patients connect and learn from each
other.”
Roni Zeiger, co-founder and CEO of Smart Patients, noted, “Together with
OncoSec, we will be able to gain a better understanding of MCC from a
patient perspective, and help design more patient-centered trials that
will make scientific breakthroughs for this disease available sooner.”
About Smart Patients
Smart Patients is an online community
for cancer patients and caregivers. The community includes a clinical
trial search engine that presents trial data from ClinicalTrials.gov in
a patient-friendly format. The community platform has been in private
beta testing since January 2013 and is now open to all cancer patients
and caregivers. To learn more, please visit us at www.smartpatients.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a
biopharmaceutical company developing its advanced-stage ImmunoPulse
DNA-based immunotherapy and NeoPulse therapy, to treat solid
tumors. ImmunoPulse and NeoPulse therapies address an unmet medical
need and represent a potential solution, for less invasive and less
expensive therapies that are able to minimize detrimental effects
resulting from currently available cancer treatments such as surgery,
systemic chemotherapy or immunotherapy and other treatment alternatives.
OncoSec Medical's core technology is based upon its proprietary use of
an electroporation platform, to dramatically enhance the delivery and
uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or
chemotherapeutic agent (NeoPulse). Treatment of various solid
cancers, using these powerful and targeted anti-cancer agents, has
demonstrated selective destruction of cancerous cells – while sparing
healthy normal tissues – during early and late stage clinical trials.
OncoSec's clinical programs include three Phase II clinical trials for
ImmunoPulse, targeting lethal skin cancers. More information is
available at http://www.oncosec.com/.
This press release contains forward looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such "forward looking statements." Forward looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties which may cause our results to differ
materially and adversely from the statements contained herein. Some of
the potential risks and uncertainties that could cause actual results to
differ from those predicted include our ability to raise additional
funding, our ability to acquire, develop or commercialize new products,
uncertainties inherent in pre-clinical studies and clinical trials,
unexpected new data, safety and technical issues, competition and market
conditions. These and additional risks and uncertainties are more fully
described in OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward looking
statements which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward looking
statements to reflect new information, events or circumstances after the
date they are made, or to reflect the occurrence of unanticipated events.